Nasdaq · CIK 0001628171
RVMD Revolution Medicines, Inc.
Insider trading from SEC Form 4. Last filing 11 d ago. Close $189.76 on Oct 9, 2026, +299% from the 52-week low and -14% from the high.
Last 90 days
Net insider value
-$48M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
16
$48M by 9 insiders
Insiders on file
12
with a Form 4 at this company
Price and insider trades, last year
RVMDOct 9, 2026 · close 189.76
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Revolution Medicines, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Alan B. Sandler Chief Development Officer sell | $1.3M 6,309 shares | -11% | +347% from low-8% from high | |
| 21Weak | Jeff Cislini SVP & General Counsel sell | $159k 765 shares | -1% | +382% from low-7% from high | |
| 16Weak | Anthony Mancini See Remarks sell | $743k 3,708 shares | -9% | +370% from low-10% from high | |
| 40Moderate | Elizabeth M Anderson director sell | $2.0M 10,143 shares | -70% | +354% from low-13% from high | |
| 25Weak | Anthony Mancini See Remarks sell | $347k 1,764 shares | -4% | +349% from low-14% from high | |
| 39Weak | Jack Anders Chief Financial Officer sell | $808k 4,053 shares | -3% | +361% from low-11% from high | |
| 30Weak | Jeff Cislini SVP & General Counsel sell | $671k 3,366 shares | -6% | +361% from low-11% from high | |
| 35Weak | Mark A Goldsmith See Remarks sell | $2.8M 13,988 shares | -5% | +361% from low-11% from high | |
| 40Moderate | Margaret A Horn Chief Operating Officer sell | $990k 4,967 shares | -3% | +361% from low-11% from high | |
| 35Weak | Stephen Michael Kelsey See Remarks sell | $1.1M 5,569 shares | -2% | +361% from low-11% from high | |
| 25Weak | Anthony Mancini See Remarks sell | $353k 1,774 shares | -4% | +361% from low-11% from high | |
| 18Weak | Alan B. Sandler Chief Development Officer sell | $68k 341 shares | -1% | +361% from low-11% from high | |
| 25Weak | Stephen Michael Kelsey See Remarks sell | $19M 92,531 shares | -24% | +379% from low-8% from high | |
| 30Weak | Anthony Mancini See Remarks sell | $3.2M 15,448 shares | -26% | +403% from low-8% from high | |
| 55Moderate | Lorence H. Kim director sell | $3.6M 17,090 shares | -100% | +413% from low-6% from high | |
| 55Moderate | Lorence H. Kim director sell | $11M 56,000 shares | -77% | +428% from low-7% from high | |
| 30Weak | Jack Anders Chief Financial Officer sell | $274k 2,753 shares | -2% | +218% from low-20% from high | |
| 24Weak | Jeff Cislini General Counsel sell | $292k 2,958 shares | -5% | +218% from low-20% from high | |
| 35Weak | Mark A Goldsmith See Remarks sell | $1.3M 12,871 shares | -4% | +218% from low-20% from high | |
| 10Weak | Mark A Goldsmith See Remarks sell | $3.6M 36,000 shares | -11% | +226% from low-18% from high | |
| 13Weak | Jeff Cislini General Counsel sell | $105k 908 shares | -2% | +278% from low-5% from high | |
| 20Weak | Jack Anders Chief Financial Officer sell | $980k 10,000 shares | -8% | +230% from low0% from high | |
| 30Weak | Jack Anders Chief Financial Officer sell | $239k 3,104 shares | -3% | +149% from low-3% from high | |
| 22Weak | Jeff Cislini General Counsel sell | $206k 2,688 shares | -5% | +149% from low-3% from high | |
| 35Weak | Mark A Goldsmith See Remarks sell | $1.2M 15,394 shares | -6% | +149% from low-3% from high | |
| 30Weak | Margaret A Horn Chief Operating Officer sell | $372k 4,847 shares | -3% | +149% from low-3% from high | |
| 26Weak | Stephen Michael Kelsey See Remarks sell | $418k 5,447 shares | -2% | +149% from low-3% from high | |
| 18Weak | Jack Anders Chief Financial Officer sell | $401k 5,418 shares | -5% | +145% from low0% from high | |
| 25Weak | Mark A Goldsmith See Remarks sell | $5.0M 66,000 shares | -21% | +145% from low0% from high | |
| 24Weak | Jeff Cislini General Counsel sell | $939k 13,388 shares | -21% | +127% from low0% from high | |
| 20Weak | Mark A Goldsmith See Remarks sell | $1.4M 20,000 shares | -7% | +127% from low0% from high | |
| 20Weak | Mark A Goldsmith See Remarks sell | $1.3M 20,000 shares | -7% | +111% from low0% from high | |
| 22Weak | Jack Anders Chief Financial Officer sell | $640k 10,000 shares | -8% | +106% from low0% from high | |
| 20Weak | Mark A Goldsmith See Remarks sell | $1.8M 30,000 shares | -8% | +96% from low-1% from high | |
| 20Weak | Jeff Cislini General Counsel sell | $660k 12,000 shares | -19% | +74% from low-11% from high | |
| 20Weak | Mark A Goldsmith See Remarks sell | $1.1M 20,000 shares | -4% | +60% from low-18% from high | |
| 20Weak | Stephen Michael Kelsey See Remarks sell | $1.2M 25,000 shares | -8% | +57% from low-20% from high | |
| 19Weak | Jeff Cislini General Counsel sell | $80k 1,799 shares | -3% | +40% from low-28% from high | |
| 27Weak | Jack Anders Chief Financial Officer sell | $106k 2,320 shares | -2% | +44% from low-26% from high | |
| 19Weak | Jeff Cislini General Counsel sell | $86k 1,869 shares | -3% | +44% from low-26% from high | |
| 30Weak | Mark A Goldsmith See Remarks sell | $615k 13,411 shares | -3% | +44% from low-26% from high | |
| 27Weak | Margaret A Horn Chief Operating Officer sell | $219k 4,775 shares | -3% | +44% from low-26% from high | |
| 23Weak | Stephen Michael Kelsey See Remarks sell | $246k 5,367 shares | -2% | +44% from low-26% from high | |
| 20Weak | Lin Wei Chief Medical Officer sell | $99k 2,160 shares | -2% | +44% from low-26% from high | |
| 30Weak | Stephen Michael Kelsey See Remarks sell | $5.6M 125,000 shares | -32% | +49% from low-24% from high | |
| 18Weak | Jack Anders Chief Financial Officer sell | $401k 10,000 shares | -8% | +27% from low-35% from high | |
| 18Weak | Jeff Cislini General Counsel sell | $76k 1,912 shares | -3% | +27% from low-35% from high | |
| 26Weak | Jack Anders Chief Financial Officer sell | $86k 2,170 shares | -2% | +28% from low-34% from high | |
| 18Weak | Jeff Cislini General Counsel sell | $75k 1,878 shares | -3% | +28% from low-34% from high | |
| 29Weak | Mark A Goldsmith See Remarks sell | $538k 13,496 shares | -3% | +28% from low-34% from high | |
| 26Weak | Margaret A Horn Chief Operating Officer sell | $140k 3,510 shares | -2% | +28% from low-34% from high | |
| 21Weak | Stephen Michael Kelsey See Remarks sell | $171k 4,289 shares | -1% | +28% from low-34% from high | |
| 19Weak | Lin Wei Chief Medical Officer sell | $87k 2,173 shares | -2% | +28% from low-34% from high | |
| 19Weak | Jeff Cislini General Counsel sell | $79k 2,041 shares | -3% | +5% from low-36% from high | |
| 25Weak | Jack Anders Chief Financial Officer sell | $73k 1,864 shares | -2% | +6% from low-35% from high | |
| 17Weak | Jeff Cislini General Counsel sell | $57k 1,458 shares | -2% | +6% from low-35% from high | |
| 27Weak | Mark A Goldsmith See Remarks sell | $458k 11,738 shares | -3% | +6% from low-35% from high | |
| 25Weak | Margaret A Horn Chief Operating Officer sell | $119k 3,058 shares | -2% | +6% from low-35% from high | |
| 21Weak | Stephen Michael Kelsey See Remarks sell | $129k 3,294 shares | -1% | +6% from low-35% from high | |
| 5Weak | Jeff Cislini General Counsel sell | $97k 2,406 shares | -6% | +1% from low-34% from high | |
| 27Weak | Jack Anders Chief Financial Officer sell | $120k 2,635 shares | -3% | - | |
| 18Weak | Jeff Cislini General Counsel sell | $73k 1,599 shares | -4% | - | |
| 28Weak | Mark A Goldsmith See Remarks sell | $532k 11,714 shares | -3% | - | |
| 27Weak | Margaret A Horn Chief Operating Officer sell | $197k 4,329 shares | -3% | - | |
| 22Weak | Stephen Michael Kelsey See Remarks sell | $212k 4,663 shares | -2% | - | |
| 50Moderate | Thilo Schroeder director buy | $60M 1,304,347 shares | +84% | - | |
| 21Weak | Jeff Cislini General Counsel sell | $141k 2,554 shares | -6% | - | |
| 20Weak | Stephen Michael Kelsey See Remarks sell | $978k 16,666 shares | -6% | - | |
| 15Weak | Jeff Cislini General Counsel sell | $360k 6,000 shares | -12% | - | |
| 25Weak | Mark A Goldsmith See Remarks sell | $3.9M 70,000 shares | -23% | - | |
| 13Weak | Sushil Patel director sell | $271k 5,000 shares | -20% | - | |
| 18Weak | Stephen Michael Kelsey See Remarks sell | $825k 16,666 shares | -6% | - | |
| 20Weak | Jack Anders Chief Financial Officer sell | $503k 10,000 shares | -9% | - | |
| 14Weak | Jeff Cislini General Counsel sell | $301k 6,000 shares | -12% | - | |
| 20Weak | Mark A Goldsmith See Remarks sell | $1.5M 30,000 shares | -9% | - | |
| 35Weak | Margaret A Horn Chief Operating Officer sell | $2.5M 50,000 shares | -27% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 29, 2026 | Alan B. Sandler Chief Development Officer | MOption exercise Common Stock10b5-1 | +6,000 | $58.84 | $353k | 58,868 | 11 d ago |
| Sep 29, 2026 | Alan B. Sandler Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -2,200 | $200.82 | $442k | 56,668 | 11 d ago |
| Sep 29, 2026 | Alan B. Sandler Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -1,609 | $201.72 | $325k | 55,059 | 11 d ago |
| Sep 29, 2026 | Alan B. Sandler Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -1,000 | $202.81 | $203k | 54,059 | 11 d ago |
| Sep 29, 2026 | Alan B. Sandler Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -1,199 | $203.91 | $244k | 52,860 | 11 d ago |
| Sep 29, 2026 | Alan B. Sandler Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -301 | $204.72 | $62k | 52,559 | 11 d ago |
| Sep 29, 2026 | Alan B. Sandler Chief Development Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 161,300 | 11 d ago |
| Sep 25, 2026 | Jeff Cislini SVP & General Counsel | SOpen-market sale Common Stock10b5-1 | -765 | $207.32 | $159k | 51,776 | 13 d ago |
| Sep 24, 2026 | Anthony Mancini See Remarks | SOpen-market sale Common Stock10b5-1 | -587 | $200.00 | $117k | 39,765 | 14 d ago |
| Sep 25, 2026 | Anthony Mancini See Remarks | MOption exercise Common Stock10b5-1 | +3,121 | $33.62 | $105k | 42,886 | 14 d ago |
| Sep 25, 2026 | Anthony Mancini See Remarks | SOpen-market sale Common Stock10b5-1 | -3,121 | $200.54 | $626k | 39,765 | 14 d ago |
| Sep 25, 2026 | Anthony Mancini See Remarks | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,121 | $0.00 | $0 | 93,625 | 14 d ago |
| Sep 22, 2026 | Elizabeth M Anderson director | MOption exercise Common Stock10b5-1 | +5,070 | $1.12 | $5,678 | 14,476 | 18 d ago |
| Sep 22, 2026 | Elizabeth M Anderson director | SOpen-market sale Common Stock10b5-1 | -910 | $191.85 | $175k | 13,566 | 18 d ago |
| Sep 22, 2026 | Elizabeth M Anderson director | SOpen-market sale Common Stock10b5-1 | -4,985 | $192.54 | $960k | 8,581 | 18 d ago |
| Sep 22, 2026 | Elizabeth M Anderson director | SOpen-market sale Common Stock10b5-1 | -2,648 | $193.44 | $512k | 5,933 | 18 d ago |
| Sep 22, 2026 | Elizabeth M Anderson director | SOpen-market sale Common Stock10b5-1 | -1,500 | $194.59 | $292k | 4,433 | 18 d ago |
| Sep 22, 2026 | Elizabeth M Anderson director | SOpen-market sale Common Stock10b5-1 | -100 | $195.15 | $20k | 4,333 | 18 d ago |
| Sep 22, 2026 | Elizabeth M Anderson director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,070 | $0.00 | $0 | 1,095 | 18 d ago |
| Sep 18, 2026 | Anthony Mancini See Remarks | SOpen-market sale Common Stock10b5-1 | -1,764 | $196.94 | $347k | 40,352 | 20 d ago |
| Sep 16, 2026 | Alan B. Sandler Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -5 | $194.96 | $975 | 53,204 | 24 d ago |
| Sep 16, 2026 | Jeff Cislini SVP & General Counsel | SOpen-market sale Common Stock10b5-1 | -52 | $195.01 | $10k | 55,855 | 24 d ago |
| Sep 16, 2026 | Jack Anders Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -61 | $195.00 | $12k | 123,208 | 24 d ago |
| Sep 16, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stock10b5-1 | -213 | $195.01 | $42k | 267,117 | 24 d ago |
| Sep 16, 2026 | Margaret A Horn Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -76 | $195.01 | $15k | 154,571 | 24 d ago |
| Sep 16, 2026 | Stephen Michael Kelsey See Remarks | SOpen-market sale Common Stock10b5-1 | -85 | $195.01 | $17k | 291,791 | 24 d ago |
| Sep 16, 2026 | Anthony Mancini See Remarks | SOpen-market sale Common Stock10b5-1 | -27 | $195.05 | $5,266 | 43,863 | 24 d ago |
| Sep 16, 2026 | Anthony Mancini See Remarks | SOpen-market sale Common Stock10b5-1 | -1,747 | $199.30 | $348k | 42,116 | 24 d ago |
| Sep 16, 2026 | Alan B. Sandler Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -336 | $199.30 | $67k | 52,868 | 24 d ago |
| Sep 16, 2026 | Jack Anders Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -3,992 | $199.30 | $796k | 119,216 | 24 d ago |
| Sep 16, 2026 | Jeff Cislini SVP & General Counsel | SOpen-market sale Common Stock10b5-1 | -3,314 | $199.30 | $660k | 52,541 | 24 d ago |
| Sep 16, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stock10b5-1 | -13,775 | $199.30 | $2.7M | 253,342 | 24 d ago |
| Sep 16, 2026 | Margaret A Horn Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -4,891 | $199.30 | $975k | 149,680 | 24 d ago |
| Sep 16, 2026 | Stephen Michael Kelsey See Remarks | SOpen-market sale Common Stock10b5-1 | -5,484 | $199.30 | $1.1M | 286,307 | 24 d ago |
| Sep 11, 2026 | Stephen Michael Kelsey See Remarks | MOption exercise Common Stock10b5-1 | +52,500 | $42.45 | $2.2M | 344,376 | 27 d ago |
| Sep 11, 2026 | Stephen Michael Kelsey See Remarks | MOption exercise Common Stock10b5-1 | +40,031 | $40.74 | $1.6M | 384,407 | 27 d ago |
| Sep 11, 2026 | Stephen Michael Kelsey See Remarks | SOpen-market sale Common Stock10b5-1 | -800 | $198.55 | $159k | 383,607 | 27 d ago |
| Sep 11, 2026 | Stephen Michael Kelsey See Remarks | SOpen-market sale Common Stock10b5-1 | -11,833 | $200.11 | $2.4M | 371,774 | 27 d ago |
| Sep 11, 2026 | Stephen Michael Kelsey See Remarks | SOpen-market sale Common Stock10b5-1 | -13,368 | $200.78 | $2.7M | 358,406 | 27 d ago |
| Sep 11, 2026 | Stephen Michael Kelsey See Remarks | SOpen-market sale Common Stock10b5-1 | -21,447 | $201.75 | $4.3M | 336,959 | 27 d ago |
| Sep 11, 2026 | Stephen Michael Kelsey See Remarks | SOpen-market sale Common Stock10b5-1 | -18,869 | $203.06 | $3.8M | 318,090 | 27 d ago |
| Sep 11, 2026 | Stephen Michael Kelsey See Remarks | SOpen-market sale Common Stock10b5-1 | -17,949 | $203.87 | $3.7M | 300,141 | 27 d ago |
| Sep 11, 2026 | Stephen Michael Kelsey See Remarks | SOpen-market sale Common Stock10b5-1 | -4,995 | $204.84 | $1.0M | 295,146 | 27 d ago |
| Sep 11, 2026 | Stephen Michael Kelsey See Remarks | SOpen-market sale Common Stock10b5-1 | -3,270 | $205.81 | $673k | 291,876 | 27 d ago |
| Sep 11, 2026 | Stephen Michael Kelsey See Remarks | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -52,500 | $42.45 | $2.2M | 0 | 27 d ago |
| Sep 11, 2026 | Stephen Michael Kelsey See Remarks | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -40,031 | $40.74 | $1.6M | 88,069 | 27 d ago |
| Sep 10, 2026 | Anthony Mancini See Remarks | MOption exercise Common Stock10b5-1 | +9,363 | $33.62 | $315k | 59,338 | 28 d ago |
| Sep 10, 2026 | Anthony Mancini See Remarks | SOpen-market sale Common Stock10b5-1 | -6,019 | $203.28 | $1.2M | 53,319 | 28 d ago |
| Sep 10, 2026 | Anthony Mancini See Remarks | SOpen-market sale Common Stock10b5-1 | -5,530 | $204.14 | $1.1M | 47,789 | 28 d ago |
| Sep 10, 2026 | Anthony Mancini See Remarks | SOpen-market sale Common Stock10b5-1 | -2,420 | $205.05 | $496k | 45,369 | 28 d ago |
| Sep 10, 2026 | Anthony Mancini See Remarks | SOpen-market sale Common Stock10b5-1 | -1,179 | $206.10 | $243k | 44,190 | 28 d ago |
| Sep 10, 2026 | Anthony Mancini See Remarks | SOpen-market sale Common Stock10b5-1 | -300 | $207.17 | $62k | 43,890 | 28 d ago |
| Sep 10, 2026 | Anthony Mancini See Remarks | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,363 | $0.00 | $0 | 96,746 | 28 d ago |
| Sep 8, 2026 | Lorence H. Kim director | SOpen-market sale Common Stockindirect: Trust10b5-1 | -706 | $206.60 | $146k | 16,384 | 32 d ago |
| Sep 8, 2026 | Lorence H. Kim director | SOpen-market sale Common Stockindirect: Trust10b5-1 | -999 | $207.33 | $207k | 15,385 | 32 d ago |
| Sep 8, 2026 | Lorence H. Kim director | SOpen-market sale Common Stockindirect: Trust10b5-1 | -3,587 | $208.55 | $748k | 11,798 | 32 d ago |
| Sep 8, 2026 | Lorence H. Kim director | SOpen-market sale Common Stockindirect: Trust10b5-1 | -2,853 | $209.56 | $598k | 8,945 | 32 d ago |
| Sep 8, 2026 | Lorence H. Kim director | SOpen-market sale Common Stockindirect: Trust10b5-1 | -4,730 | $210.50 | $996k | 4,215 | 32 d ago |
| Sep 8, 2026 | Lorence H. Kim director | SOpen-market sale Common Stockindirect: Trust10b5-1 | -3,844 | $211.36 | $812k | 371 | 32 d ago |
| Sep 8, 2026 | Lorence H. Kim director | SOpen-market sale Common Stockindirect: Trust10b5-1 | -371 | $212.27 | $79k | 0 | 32 d ago |
| Aug 31, 2026 | Lorence H. Kim director | SOpen-market sale Common Stockindirect: Trust10b5-1 | -300 | $200.56 | $60k | 72,790 | 40 d ago |
| Aug 31, 2026 | Lorence H. Kim director | SOpen-market sale Common Stockindirect: Trust10b5-1 | -6,597 | $201.47 | $1.3M | 66,193 | 40 d ago |
| Aug 31, 2026 | Lorence H. Kim director | SOpen-market sale Common Stockindirect: Trust10b5-1 | -12,919 | $202.48 | $2.6M | 53,274 | 40 d ago |
| Aug 31, 2026 | Lorence H. Kim director | SOpen-market sale Common Stockindirect: Trust10b5-1 | -26,160 | $203.55 | $5.3M | 27,114 | 40 d ago |
| Aug 31, 2026 | Lorence H. Kim director | SOpen-market sale Common Stockindirect: Trust10b5-1 | -7,271 | $204.35 | $1.5M | 19,843 | 40 d ago |
| Aug 31, 2026 | Lorence H. Kim director | SOpen-market sale Common Stockindirect: Trust10b5-1 | -2,128 | $205.19 | $437k | 17,715 | 40 d ago |
| Aug 31, 2026 | Lorence H. Kim director | SOpen-market sale Common Stockindirect: Trust10b5-1 | -625 | $206.15 | $129k | 17,090 | 40 d ago |
| Mar 17, 2026 | Jack Anders Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -2,753 | $99.48 | $274k | 125,512 | Mar 19, 2026 |
| Mar 17, 2026 | Jeff Cislini General Counsel | SOpen-market sale Common Stock10b5-1 | -1,795 | $99.48 | $179k | 59,681 | Mar 19, 2026 |
| Mar 17, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stock10b5-1 | -12,871 | $99.48 | $1.3M | 276,698 | Mar 19, 2026 |
| Mar 19, 2026 | Jeff Cislini General Counsel | SOpen-market sale Common Stock10b5-1 | -1,163 | $97.44 | $113k | 58,518 | Mar 19, 2026 |
| Mar 4, 2026 | Elizabeth M Anderson director | GGift Common Stock | -15,000 | $0.00 | $0 | 8,215 | Mar 6, 2026 |
| Mar 4, 2026 | Elizabeth M Anderson director | GGift Common Stockindirect: See footnote | +15,000 | $0.00 | $0 | 15,000 | Mar 6, 2026 |
| Mar 1, 2026 | Jack Anders Chief Financial Officer | AGrant or award Common Stock | +20,200 | $0.00 | $0 | 128,265 | Mar 3, 2026 |
| Mar 1, 2026 | Jeff Cislini General Counsel | AGrant or award Common Stock | +14,500 | $0.00 | $0 | 61,476 | Mar 3, 2026 |
| Mar 1, 2026 | Mark A Goldsmith See Remarks | AGrant or award Common Stock10b5-1 | +57,100 | $0.00 | $0 | 289,569 | Mar 3, 2026 |
| Mar 2, 2026 | Mark A Goldsmith See Remarks | MOption exercise Common Stock10b5-1 | +30,000 | $4.09 | $123k | 319,569 | Mar 3, 2026 |
| Mar 1, 2026 | Jack Anders Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +45,400 | $0.00 | $0 | 45,400 | Mar 3, 2026 |
| Mar 1, 2026 | Jeff Cislini General Counsel | AGrant or award Stock Option (Right to Buy)derivative | +32,500 | $0.00 | $0 | 32,500 | Mar 3, 2026 |
| Mar 2, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stock10b5-1 | -700 | $98.17 | $69k | 318,869 | Mar 3, 2026 |
| Mar 2, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stock10b5-1 | -3,500 | $99.76 | $349k | 315,369 | Mar 3, 2026 |
| Mar 2, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stock10b5-1 | -3,620 | $100.73 | $365k | 311,749 | Mar 3, 2026 |
| Mar 2, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stock10b5-1 | -21,329 | $101.60 | $2.2M | 290,420 | Mar 3, 2026 |
| Mar 2, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stock10b5-1 | -851 | $102.20 | $87k | 289,569 | Mar 3, 2026 |
| Mar 2, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stockindirect: Trust10b5-1 | -100 | $98.31 | $9,831 | 67,324 | Mar 3, 2026 |
| Mar 2, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stockindirect: Trust10b5-1 | -400 | $100.12 | $40k | 66,924 | Mar 3, 2026 |
| Mar 2, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stockindirect: Trust10b5-1 | -1,700 | $101.47 | $173k | 65,224 | Mar 3, 2026 |
| Mar 2, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stockindirect: Trust10b5-1 | -800 | $102.00 | $82k | 64,424 | Mar 3, 2026 |
| Mar 2, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stockindirect: Trust10b5-1 | -100 | $98.29 | $9,829 | 67,324 | Mar 3, 2026 |
| Mar 2, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stockindirect: Trust10b5-1 | -600 | $100.19 | $60k | 66,724 | Mar 3, 2026 |
| Mar 2, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stockindirect: Trust10b5-1 | -2,100 | $101.63 | $213k | 64,624 | Mar 3, 2026 |
| Mar 2, 2026 | Mark A Goldsmith See Remarks | SOpen-market sale Common Stockindirect: Trust10b5-1 | -200 | $102.08 | $20k | 64,424 | Mar 3, 2026 |
| Mar 1, 2026 | Mark A Goldsmith See Remarks | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +128,600 | $0.00 | $0 | 128,600 | Mar 3, 2026 |
| Mar 2, 2026 | Mark A Goldsmith See Remarks | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -30,000 | $0.00 | $0 | 47,708 | Mar 3, 2026 |
| Feb 6, 2026 | Mark A Goldsmith See Remarks | MOption exercise Common Stock | +24,010 | $0.54 | $13k | 256,479 | Feb 10, 2026 |
| Feb 6, 2026 | Mark A Goldsmith See Remarks | MOption exercise Stock Option (Right to Buy)derivative | -24,010 | $0.00 | $0 | 144,493 | Feb 10, 2026 |
| Jan 21, 2026 | Jeff Cislini General Counsel | SOpen-market sale Common Stock10b5-1 | -908 | $115.60 | $105k | 46,976 | Jan 23, 2026 |
| Jan 7, 2026 | Jack Anders Chief Financial Officer | MOption exercise Common Stock10b5-1 | +10,000 | $42.45 | $425k | 118,065 | Jan 9, 2026 |
| Jan 7, 2026 | Jack Anders Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $98.00 | $980k | 108,065 | Jan 9, 2026 |
| Jan 7, 2026 | Jack Anders Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 15,900 | Jan 9, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Elizabeth M Andersondirector
- Jack AndersChief Financial Officer
- Jeff CisliniGeneral Counsel
- Mark A GoldsmithSee Remarks
- Margaret A HornChief Operating Officer
- Stephen Michael KelseySee Remarks
- Lorence H. Kimdirector
- Anthony ManciniSee Remarks
- Sushil Pateldirector, ceo, officer
- Alan B. SandlerChief Development Officer
- Thilo Schroederdirector
- Lin WeiChief Medical Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.